solufenum: water-soluble salt of ibuprofen; structure in fourth source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9841440 |
| CHEMBL ID | 1201141 |
| SCHEMBL ID | 44617 |
| MeSH ID | M0065869 |
| Synonym |
|---|
| p-isobutylphenyl-2-propionate lysine |
| l-lysine mono(4-isobutyl-alpha-methylbenzeneacetate) |
| soluphene |
| l-lysine, mono(alpha-methyl-4-(2-methylpropyl)benzeneacetate) |
| solufen [spanish] |
| einecs 260-751-7 |
| ibuprofen lysinate |
| saren |
| dolormin |
| neoprofen (tn) |
| D06606 |
| ibuprofen l-lysine (jan) |
| 57469-77-9 |
| solufenum |
| ibuprofen lysine (usan) |
| neoprofen |
| lisiprofen |
| ibuprofen l-lysine |
| imbun |
| CHEMBL1201141 |
| ibuprofen lysine |
| A831448 |
| (2s)-2,6-diaminohexanoic acid; 2-(4-isobutylphenyl)propanoic acid;ibuprofen lysine |
| AKOS015994629 |
| BCP9000769 |
| unii-n01orx9d6s |
| n01orx9d6s , |
| arflamin |
| ibuprofen lysine [usan] |
| S1518 |
| SCHEMBL44617 |
| HS-0089 |
| AB01274868-01 |
| (s)-2,6-diaminohexanoic acid compound with 2-(4-isobutylphenyl)propanoic acid (1:1) |
| DTXSID50432054 , |
| AB01274868_02 |
| l-lysine mono((2rs)-2-(4-(2-methylpropyl)phenyl)propanoate |
| l-lysine compound with 2-(4-isobutylphenyl)propanoic acid (1:1) |
| HY-100586 |
| ibuprofen (l-lysine) |
| l-lysine, .alpha.-methyl-4-(2-methylpropyl)benzeneacetate (1:1) |
| ibuprofen lysinate [who-dd] |
| ibuprofen lysine [vandf] |
| ibuprofen l-lysine [jan] |
| l-lysine, mono(.alpha.-methyl-4-(2-methylpropyl)benzeneacetate) |
| ibuprofen lysine [mart.] |
| ibuprofen lysine [orange book] |
| ibuprofen lysine (neoprofen) |
| (s)-2,6-diaminohexanoic acid 2-(4-isobutylphenyl)propanoic acid salt |
| (2s)-2,6-diaminohexanoic acid;2-[4-(2-methylpropyl)phenyl]propanoic acid |
| CCG-268058 |
| Q27284326 |
| D81763 |
| [(5s)-5-amino-5-carboxypentyl]azanium;2-[4-(2-methylpropyl)phenyl]propanoate |
| ibuprofen-lysinat |
| DTXSID201024433 |
| CS-0019739 |
| ibuprofen lysine (mart.) |
| l-lysine, alpha-methyl-4-(2-methylpropyl)benzeneacetate (1:1) |
| dtxcid10382884 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " From the results of intravenous injections one can deduce linear ibuprofen pharmacokinetics within the considered dosage range, with corresponding AUC0-infinity values of 3786 micrograms * min ml-1 and 7260 micrograms * min ml-1 for the 200 mg and 400 mg doses, respectively." | ( Pharmacokinetics and absolute bioavailability of ibuprofen after oral administration of ibuprofen lysine in man. Augustin, J; Kerkmann, T; Koselowske, G; Mangold, B; Martin, W; Töberich, H, 1990) | 0.28 |
| " Dosing schemes were proposed as a function of postnatal age, to achieve this AUC and to improve the efficacy of treatment for patent ductus arteriosus in neonates." | ( An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study. Eisinger, MJ; Hirt, D; Langhendries, JP; Marguglio, A; Schepens, P; Treluyer, JM; Urien, S; Van Overmeire, B, 2008) | 0.35 |
| "Pharmaceutical industry has been encountering antimicrobial activity of non-antibiotics during suitability tests carried out prior to routine pharmacopoeial microbiological purity analysis of finished dosage forms." | ( Antimicrobial activity of ibuprofen: new perspectives on an "Old" non-antibiotic drug. Kos, B; Obad, J; Šušković, J, 2015) | 0.42 |
| " The aim of the study was to evaluate the taste masking effectiveness of Smartseal 30D and ReadyMix on a range of bitter drug substances such as diphenhydramine HCl (DPD), ibuprofen lysine (IBU-LS), and phenylephrine HCl (PPH) for the development of paediatric dosage forms." | ( Comparative taste-masking evaluation of microencapsulated bitter drugs using Smartseal 30D and ReadyMix for paediatric dosage forms. Douroumis, D; Mithu, MSH; Muoka, LC; Nandi, U; Ross, SA, 2021) | 0.62 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 7 (17.07) | 18.7374 |
| 1990's | 6 (14.63) | 18.2507 |
| 2000's | 12 (29.27) | 29.6817 |
| 2010's | 15 (36.59) | 24.3611 |
| 2020's | 1 (2.44) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 14 (31.82%) | 5.53% |
| Reviews | 1 (2.27%) | 6.00% |
| Case Studies | 2 (4.55%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 27 (61.36%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||